What is HC Wainwright’s Estimate for INKT Q1 Earnings?

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of MiNK Therapeutics in a research report issued on Tuesday, February 25th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.51) for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($0.77) EPS, FY2027 earnings at ($0.73) EPS and FY2028 earnings at ($0.45) EPS.

Separately, Robert W. Baird reduced their target price on MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating for the company in a research note on Friday, November 15th.

MiNK Therapeutics Price Performance

Shares of INKT opened at $9.26 on Thursday. The stock has a 50-day moving average of $8.47 and a 200-day moving average of $7.74. The company has a market cap of $36.69 million, a PE ratio of -2.37 and a beta of 0.17. MiNK Therapeutics has a one year low of $4.56 and a one year high of $19.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.